PRMT1 promotes glucose toxicity-induced β cell dysfunction by regulating the nucleo-cytoplasmic trafficking of PDX-1 in a FOXO1-dependent manner in INS-1 cells

Endocrine. 2015 Aug;49(3):669-82. doi: 10.1007/s12020-015-0543-8. Epub 2015 Feb 10.

Abstract

Protein N-arginine methyltransferase-1 (PRMT1), the major asymmetric arginine methyltransferase, plays important roles in various cellular processes. Previous reports have demonstrated that levels and activities of PRMT1 can vary in animals with type 2 diabetes mellitus. The aim of this study was to assess the expression and mechanism of action of PRMT1 during glucose toxicity-induced β cell dysfunction. Liposome-mediated gene transfection was used to transfect INS-1 cells with siPRMT1, which inhibits PRMT1 expression, and pALTER-FOXO1, which overexpresses forkhead box protein O1 (FOXO1). The cells were then cultured in media containing 5.6 or 25 mmol/L glucose with or without the small molecule PRMT1 inhibitor AMI-1 for 48 h. The protein levels of PRMT1, the arginine methylated protein α-metR, FOXO1, Phospho-FOXO1, pancreas duodenum homeobox-1 (PDX-1), and the intracellular localization of PDX-1 and FOXO1 were then measured by western blotting. FOXO1 methylation was detected by immunoprecipitated with anti-PRMT1 antibody and were immunoblotted with α-metR. The levels of insulin mRNA were measured by real-time fluorescence quantitative PCR. Glucose-stimulated insulin secretion (GSIS) and intracellular insulin content were measured using radioimmunoassays. Intracellular Ca(2+) ([Ca(2+)]i) was detected using Fura-2 AM. Intracellular cAMP levels were measured using ELISA. Chronic exposure to high glucose impaired insulin secretion, decreased insulin mRNA levels and insulin content, increased intracellular [Ca(2+)]i and cAMP levels, and abolishes their responses to glucose. Inhibiting PRMT1 expression improved insulin secretion, increased mRNA levels and insulin content by regulating the intracellular translocation of PDX-1 and FOXO1, decreasing the methylation of FOXO1, and reducing intracellular [Ca(2+)]i and cAMP concentrations. Transient overexpression of constitutively active FOXO1 in nuclear reversed the AMI-1-induced improvement of β cell function without changing arginine methylation. It is concluded therefore that PRMT1 regulates GSIS in INS-1 cells, through enhanced methylation-induced nuclear localization of FOXO1, which subsequently suppresses the nuclear localization of PDX-1. Our results suggest a novel mechanism that might contribute to the deficient insulin secretion observed under conditions of chronically hyperglycemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcium Signaling / drug effects
  • Calcium Signaling / genetics
  • Cell Line
  • Cyclic AMP / metabolism
  • Enzyme Inhibitors / pharmacology
  • Forkhead Box Protein O1
  • Forkhead Transcription Factors / genetics*
  • Gene Silencing
  • Glucose / toxicity*
  • Homeodomain Proteins / genetics*
  • Humans
  • Insulin / biosynthesis
  • Insulin-Secreting Cells / drug effects*
  • Liposomes
  • Pancreatic Diseases / genetics*
  • Protein-Arginine N-Methyltransferases / antagonists & inhibitors
  • Protein-Arginine N-Methyltransferases / genetics*
  • RNA, Messenger / biosynthesis
  • Repressor Proteins / antagonists & inhibitors
  • Repressor Proteins / genetics*
  • Trans-Activators / genetics*
  • Transfection

Substances

  • Enzyme Inhibitors
  • FOXO1 protein, human
  • Forkhead Box Protein O1
  • Forkhead Transcription Factors
  • Homeodomain Proteins
  • Insulin
  • Liposomes
  • RNA, Messenger
  • Repressor Proteins
  • Trans-Activators
  • pancreatic and duodenal homeobox 1 protein
  • Cyclic AMP
  • PRMT1 protein, human
  • Protein-Arginine N-Methyltransferases
  • Glucose